EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Commentary on “Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors”

Marc Lecoultre, Aya El Helali

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2025-012218 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Marc Lecoultre und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Hematology, University Hospital Zurich, Zürich, Switzerland. Hauptthemen laut MEDLINE: Neoplasms, Tumor-Associated Macrophages, Adenoviridae, Oncolytic Virotherapy. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tumor-associated macrophages (TAMs), long exploited by cancers to evade immune detection, can now be reprogrammed into potent antitumor effectors through cutting-edge viral engineering. In a landmark study published in the Journal for Immunotherapy of Cancer , Zhang et al introduced an innovative adenovirus, Adv-mSS, that blocks two critical “don’t eat me” signals, CD47 and CD24, used by tumors to paralyze macrophage activity. By converting immunosuppressive TAMs into tumor-engulfing predators and reigniting CD8 T-cell response, Adv-mSS eradicated tumors across multiple preclinical models. This strategy offers a promising avenue for activating both innate and adaptive immunity against cancer and may address key limitations of current immunotherapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsTumor-Associated MacrophagesAdenoviridaeOncolytic VirotherapyReceptors, ImmunologicOncolytic VirusesAntigens, DifferentiationHumansAnimalsImmunotherapy

Stichwörter der Autor:innen

Immune modulatoryMacrophageOncolytic virusTumor microenvironment - TME

Substanzen

Receptors, ImmunologicSIRPA protein, humanAntigens, Differentiation

Autor:innen und Institutionen

  • Department of Medical Oncology and Hematology, University Hospital Zurich, Zürich, Switzerland.
  • Department of Clinical Oncology, Centre of Cancer Medicine, The University of Hong Kong, Hong Kong, Hong Kong ahelali@hku.hk.

Zitieren

APA

Lecoultre, M., & El Helali, A. (2025). Commentary on “Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors”. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-012218

Vancouver

Lecoultre M, El Helali A. Commentary on “Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors”. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2025-012218

BibTeX
@article{Lecoultre2025,
  author = {Lecoultre, Marc and El Helali, Aya},
  title = {Commentary on “Targeted release of a bispecific fusion protein SIRPα/Siglec-10 by oncolytic adenovirus reinvigorates tumor-associated macrophages to improve therapeutic outcomes in solid tumors”},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2025-012218}
}
Kostenlos starten →